Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$245.11
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | BIIB Avg Daily Volume: 1,881,600
Last Update: 02/11/16 - 4:00 PM EST
Volume: 0
YTD Performance: -20.01%
Open: $0.00
Previous Close: $245.11
52 Week Range: $243.03 - $480.18
Oustanding Shares: 218,672,717
Market Cap: 55,149,259,227
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 12 12 11
Moderate Buy 2 2 2 2
Hold 8 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.88 1.74 1.74 1.77
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 16.48
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
16.48 16.40 27.18
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-16.62% -37.15% 49.45%
GROWTH 12 Mo 3 Yr CAGR
Revenue 46.50 0.95 0.25
Net Income 22.20 1.60 0.37
EPS 24.00 1.65 0.38
Earnings for BIIB:
EBITDA 4.06B
Revenue 9.42B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $4.45 $4.60 $18.62 $20.19
Number of Analysts 20 20 21 21
High Estimate $4.80 $4.88 $19.45 $22.07
Low Estimate $4.00 $4.27 $18.02 $18.61
Prior Year $3.82 $4.22 $17.01 $18.62
Growth Rate (Year over Year) 16.43% 9.02% 9.47% 8.43%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Is the biotech company's stock on its way higher?
The stock may be on its way higher.
BIIB needs to announce some top-line suprises when it reports on Wednesday to spark investor enthusiasm.
BIIB's action since late November has been constructive. 
I chose stocks that I believe present the best investment opportunity right now.
I picked the stocks that I believe present the best investment opportunity right now.
There are more bad cards in the deck than good ones right now, but that's no reason to quit the game.
Let's break it down into several components.

Columnist Conversations

Should read... The U.S. dollar continued to experience WEAKNESS
Reasons to trail down stops on shorts in the indices and also to consider longs if the buy signals fire off......
JPMorgan Chase's CEO Jamie Dimon buys 500K shares of the company - CNBC, citing DJ
Bunge (BG) reported so-so earnings today while warning the new year is starting off dully. The shares were de...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.